Movement Alert｜Argenx SE Falls 3.02% in Regular Trading, Earnings Near and Prior Clinical Setback Remain in Focus

Market Focus10-16 23:08

On October 16, Argenx SE fell 3.02% in Regular Trading, trading at $821.18, with turnover of $83.4514 million.

The move coincided with investor focus shifting toward the company’s October 22 earnings release, with the market continuing to weigh Vyvgart sales momentum and profit elasticity against lingering sensitivity after the discontinuation of the Phase 3 UNITY study in Sjogren's disease.

Current market expectations call for quarterly revenue growth of 58.46% year over year and EPS of $7.44. In the prior quarter, Argenx SE reported revenue of $1.541 billion, up 59.33% year over year, and net profit of $472 million. The earlier UNITY study termination was based on futility at interim analysis, while the company said no new safety signal was observed, leaving the stock more sensitive to upcoming earnings execution.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment